The use of liposomal BPD-PDT been shown to lead to the downregulation of Bcl-xl and enhance the Bax/Bcl-xl ratio, promoting pro-apoptotic activity and inducing complete killing in various pancreatic cancer lines, including the gemcitabine-resistant lines [36]. This evidence concerns the gene BCL2L1 and pancreatic neoplasm.